Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy

Kyung Hyun Min, Kyeongsoon Park, Yoo Shin Kim, Sang Mun Bae, Seulki Lee, Hyung Gon Jo, Rang Woon Park, In-San Kim, Seo Young Jeong, Kwang Meyung Kim, Ick Chan Kwon

Research output: Contribution to journalArticle

338 Citations (Scopus)

Abstract

To prepare a water-insoluble camptothecin (CPT) delivery carrier, hydrophobically modified glycol chitosan (HGC) nanoparticles were constructed by chemical conjugation of hydrophobic 5β-cholanic acid moieties to the hydrophilic glycol chitosan backbone. Insoluble anticancer drug, CPT, was easily encapsulated into HGC nanoparticles by a dialysis method and the drug loading efficiency was above 80%. CPT-encapsulated HGC (CPT-HGC) nanoparticles formed nano-sized self-aggregates in aqueous media (280-330 nm in diameter) and showed sustained release of CPT for 1 week. Also, HGC nanoparticles effectively protected the active lactone ring of CPT from the hydrolysis under physiological condition, due to the encapsulation of CPT into the hydrophobic cores in the HGC nanoparticles. The CPT-HGC nanoparticles exhibited significant antitumor effects and high tumor targeting ability towards MDA-MB231 human breast cancer xenografts subcutaneously implanted in nude mice. Tumor growth was significantly inhibited after i.v. injection of CPT-HGC nanoparticles at doses of 10 mg/kg and 30 mg/kg, compared to free CPT at dose of 30 mg/kg. The significant antitumor efficacy of CPT-HGC nanoparticles was attributed to the ability of the nanoparticles to show both prolonged blood circulation and high accumulation in tumors, as confirmed by near infrared (NIR) fluorescence imaging systems. Thus, the delivery of CPT to tumor tissues at a high concentration, with the assistance of HGC nanoparticles, exerted a potent therapeutic effect. These results reveal the promising potential of HGC nanoparticles-encapsulated CPT as a stable and effective drug delivery system in cancer therapy.

Original languageEnglish
Pages (from-to)208-218
Number of pages11
JournalJournal of Controlled Release
Volume127
Issue number3
DOIs
Publication statusPublished - 2008 May 8
Externally publishedYes

Fingerprint

Drug Stability
Camptothecin
Nanoparticles
Neoplasms
Therapeutics
glycol-chitosan
Blood Circulation
Optical Imaging
Therapeutic Uses
Lactones
Drug Delivery Systems
Heterografts
Nude Mice
Pharmaceutical Preparations
Dialysis

Keywords

  • Anticancer drug delivery system
  • Breast cancer
  • Camptothecin (CPT)
  • Cancer therapy
  • Hydrophobically modified glycol chitosan nanoparticles (HGC)

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. / Min, Kyung Hyun; Park, Kyeongsoon; Kim, Yoo Shin; Bae, Sang Mun; Lee, Seulki; Jo, Hyung Gon; Park, Rang Woon; Kim, In-San; Jeong, Seo Young; Kim, Kwang Meyung; Kwon, Ick Chan.

In: Journal of Controlled Release, Vol. 127, No. 3, 08.05.2008, p. 208-218.

Research output: Contribution to journalArticle

Min, Kyung Hyun ; Park, Kyeongsoon ; Kim, Yoo Shin ; Bae, Sang Mun ; Lee, Seulki ; Jo, Hyung Gon ; Park, Rang Woon ; Kim, In-San ; Jeong, Seo Young ; Kim, Kwang Meyung ; Kwon, Ick Chan. / Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. In: Journal of Controlled Release. 2008 ; Vol. 127, No. 3. pp. 208-218.
@article{2605967bec794d00844a3fffb9904a24,
title = "Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy",
abstract = "To prepare a water-insoluble camptothecin (CPT) delivery carrier, hydrophobically modified glycol chitosan (HGC) nanoparticles were constructed by chemical conjugation of hydrophobic 5β-cholanic acid moieties to the hydrophilic glycol chitosan backbone. Insoluble anticancer drug, CPT, was easily encapsulated into HGC nanoparticles by a dialysis method and the drug loading efficiency was above 80{\%}. CPT-encapsulated HGC (CPT-HGC) nanoparticles formed nano-sized self-aggregates in aqueous media (280-330 nm in diameter) and showed sustained release of CPT for 1 week. Also, HGC nanoparticles effectively protected the active lactone ring of CPT from the hydrolysis under physiological condition, due to the encapsulation of CPT into the hydrophobic cores in the HGC nanoparticles. The CPT-HGC nanoparticles exhibited significant antitumor effects and high tumor targeting ability towards MDA-MB231 human breast cancer xenografts subcutaneously implanted in nude mice. Tumor growth was significantly inhibited after i.v. injection of CPT-HGC nanoparticles at doses of 10 mg/kg and 30 mg/kg, compared to free CPT at dose of 30 mg/kg. The significant antitumor efficacy of CPT-HGC nanoparticles was attributed to the ability of the nanoparticles to show both prolonged blood circulation and high accumulation in tumors, as confirmed by near infrared (NIR) fluorescence imaging systems. Thus, the delivery of CPT to tumor tissues at a high concentration, with the assistance of HGC nanoparticles, exerted a potent therapeutic effect. These results reveal the promising potential of HGC nanoparticles-encapsulated CPT as a stable and effective drug delivery system in cancer therapy.",
keywords = "Anticancer drug delivery system, Breast cancer, Camptothecin (CPT), Cancer therapy, Hydrophobically modified glycol chitosan nanoparticles (HGC)",
author = "Min, {Kyung Hyun} and Kyeongsoon Park and Kim, {Yoo Shin} and Bae, {Sang Mun} and Seulki Lee and Jo, {Hyung Gon} and Park, {Rang Woon} and In-San Kim and Jeong, {Seo Young} and Kim, {Kwang Meyung} and Kwon, {Ick Chan}",
year = "2008",
month = "5",
day = "8",
doi = "10.1016/j.jconrel.2008.01.013",
language = "English",
volume = "127",
pages = "208--218",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy

AU - Min, Kyung Hyun

AU - Park, Kyeongsoon

AU - Kim, Yoo Shin

AU - Bae, Sang Mun

AU - Lee, Seulki

AU - Jo, Hyung Gon

AU - Park, Rang Woon

AU - Kim, In-San

AU - Jeong, Seo Young

AU - Kim, Kwang Meyung

AU - Kwon, Ick Chan

PY - 2008/5/8

Y1 - 2008/5/8

N2 - To prepare a water-insoluble camptothecin (CPT) delivery carrier, hydrophobically modified glycol chitosan (HGC) nanoparticles were constructed by chemical conjugation of hydrophobic 5β-cholanic acid moieties to the hydrophilic glycol chitosan backbone. Insoluble anticancer drug, CPT, was easily encapsulated into HGC nanoparticles by a dialysis method and the drug loading efficiency was above 80%. CPT-encapsulated HGC (CPT-HGC) nanoparticles formed nano-sized self-aggregates in aqueous media (280-330 nm in diameter) and showed sustained release of CPT for 1 week. Also, HGC nanoparticles effectively protected the active lactone ring of CPT from the hydrolysis under physiological condition, due to the encapsulation of CPT into the hydrophobic cores in the HGC nanoparticles. The CPT-HGC nanoparticles exhibited significant antitumor effects and high tumor targeting ability towards MDA-MB231 human breast cancer xenografts subcutaneously implanted in nude mice. Tumor growth was significantly inhibited after i.v. injection of CPT-HGC nanoparticles at doses of 10 mg/kg and 30 mg/kg, compared to free CPT at dose of 30 mg/kg. The significant antitumor efficacy of CPT-HGC nanoparticles was attributed to the ability of the nanoparticles to show both prolonged blood circulation and high accumulation in tumors, as confirmed by near infrared (NIR) fluorescence imaging systems. Thus, the delivery of CPT to tumor tissues at a high concentration, with the assistance of HGC nanoparticles, exerted a potent therapeutic effect. These results reveal the promising potential of HGC nanoparticles-encapsulated CPT as a stable and effective drug delivery system in cancer therapy.

AB - To prepare a water-insoluble camptothecin (CPT) delivery carrier, hydrophobically modified glycol chitosan (HGC) nanoparticles were constructed by chemical conjugation of hydrophobic 5β-cholanic acid moieties to the hydrophilic glycol chitosan backbone. Insoluble anticancer drug, CPT, was easily encapsulated into HGC nanoparticles by a dialysis method and the drug loading efficiency was above 80%. CPT-encapsulated HGC (CPT-HGC) nanoparticles formed nano-sized self-aggregates in aqueous media (280-330 nm in diameter) and showed sustained release of CPT for 1 week. Also, HGC nanoparticles effectively protected the active lactone ring of CPT from the hydrolysis under physiological condition, due to the encapsulation of CPT into the hydrophobic cores in the HGC nanoparticles. The CPT-HGC nanoparticles exhibited significant antitumor effects and high tumor targeting ability towards MDA-MB231 human breast cancer xenografts subcutaneously implanted in nude mice. Tumor growth was significantly inhibited after i.v. injection of CPT-HGC nanoparticles at doses of 10 mg/kg and 30 mg/kg, compared to free CPT at dose of 30 mg/kg. The significant antitumor efficacy of CPT-HGC nanoparticles was attributed to the ability of the nanoparticles to show both prolonged blood circulation and high accumulation in tumors, as confirmed by near infrared (NIR) fluorescence imaging systems. Thus, the delivery of CPT to tumor tissues at a high concentration, with the assistance of HGC nanoparticles, exerted a potent therapeutic effect. These results reveal the promising potential of HGC nanoparticles-encapsulated CPT as a stable and effective drug delivery system in cancer therapy.

KW - Anticancer drug delivery system

KW - Breast cancer

KW - Camptothecin (CPT)

KW - Cancer therapy

KW - Hydrophobically modified glycol chitosan nanoparticles (HGC)

UR - http://www.scopus.com/inward/record.url?scp=42049121123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049121123&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2008.01.013

DO - 10.1016/j.jconrel.2008.01.013

M3 - Article

VL - 127

SP - 208

EP - 218

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -